{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T10:24:58Z","timestamp":1793269498779,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Carbapenemase-producing Enterobacterales (CPE) are a significant public health concern, with limited treatment options and high mortality rates. The epidemiology and management of CPE infections in France remain insufficiently documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide a multicentre snapshot of the management of CPE infections in France, assess current clinical practices and evaluate their alignment with international guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a multicenter, observational, cross-sectional study across 31 French hospitals between September 2021 and March 2023. Adult patients with confirmed CPE infections were included. Clinical and microbiological data were collected retrospectively. Treatment regimens were analysed, and therapeutic appropriateness was assessed based on European and international guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 6936 screened patients, 96 met the inclusion criteria. The most frequently isolated pathogens were Klebsiella pneumoniae (42%), Escherichia coli (18%) and Enterobacter cloacae complex (16%). OXA-48-like carbapenemases were predominant (50%), followed by New Delhi metallo-\u03b2-lactamase (NDM) (38%). Initial empirical therapy was administered in 92.7% of patients overall; appropriateness was 50% in OXA-48-like infections and 25.5% in NDM infections. On multivariable analysis, 30-day mortality (34%) was associated with comorbidity burden and septic shock, whereas neither time to appropriate therapy nor therapy appropriateness independently predicted death. These data suggest outcomes were mainly driven by patient factors and severity, despite low empirical appropriateness\u2014particularly for NDM\u2014which supports efforts to improve early targeting through rapid diagnostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the challenges associated with CPE infections, including high mortality and frequent inappropriate empirical therapy. Our findings emphasize the need for optimized antimicrobial stewardship and rapid microbiological diagnostics to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf260","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:20:02Z","timestamp":1767615602000},"source":"Crossref","is-referenced-by-count":2,"title":["Management of infections caused by carbapenemase-producing Enterobacterales in France: a real-world study"],"prefix":"10.1093","volume":"8","author":[{"given":"B","family":"Pilmis","sequence":"first","affiliation":[{"name":"Department of Clinical Microbiology, Saint-Joseph & Marie-Lannelongue Hospitals , Paris ,","place":["France"]},{"name":"Micalis Institute UMR 1319, Universit\u00e9 Paris-Saclay, INRAe, AgroParisTech , Orsay ,","place":["France"]},{"name":"Faculty of Medicine, Team \u2018Resist\u2019 UMR1184 \u2018Immunology of Viral, Auto-Immune, Hematological, and Bacterial Diseases (IMVA-HB),\u2019 INSERM, Universit\u00e9 Paris-Saclay, CEA , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Escaut","sequence":"additional","affiliation":[{"name":"Department of Infectious and Tropical Diseases, Assistance Publique\u2013H\u00f4pitaux de Paris, Bic\u00eatre Hospital, Paris-Saclay University , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Seguret","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Surgical Intensive Care, Bic\u00eatre Hospital, Paris-Saclay University, Assistance Publique\u2013H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Weber","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Surgical Intensive Care, Bic\u00eatre Hospital, Paris-Saclay University, Assistance Publique\u2013H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Bussy","sequence":"additional","affiliation":[{"name":"Department of Bacteriology-Hygiene, Bic\u00eatre Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Faculty of Medicine and Paris-Sud University , le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Department of Anesthesia and Surgical Intensive Care, Bic\u00eatre Hospital, Paris-Saclay University, Assistance Publique\u2013H\u00f4pitaux de Paris , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6596-7384","authenticated-orcid":false,"given":"L","family":"Dortet","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Team \u2018Resist\u2019 UMR1184 \u2018Immunology of Viral, Auto-Immune, Hematological, and Bacterial Diseases (IMVA-HB),\u2019 INSERM, Universit\u00e9 Paris-Saclay, CEA , Le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Department of Bacteriology-Hygiene, Bic\u00eatre Hospital, Assistance Publique\u2013H\u00f4pitaux de Paris, Faculty of Medicine and Paris-Sud University , le Kremlin-Bic\u00eatre ,","place":["France"]},{"name":"Associated French National Reference Center for Antibiotic Resistance: Carbapenemase-Producing Enterobacterales , Le Kremlin-Bic\u00eatre ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,9]]},"reference":[{"key":"2026012903423513100_dlaf260-B1","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/cid\/ciaa122","article-title":"Carbapenem-resistant Enterobacterales, carbapenem resistant organisms, carbapenemase-producing Enterobacterales, and carbapenemase-producing organisms: terminology past its \u2018sell-by date\u2019 in an era of new antibiotics and regional carbapenemase epidemiology","volume":"71","author":"Livermore","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026012903423513100_dlaf260-B2","doi-asserted-by":"publisher","first-page":"dlac098","DOI":"10.1093\/jacamr\/dlac098","article-title":"Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime\/avibactam and comparator agents","volume":"4","author":"Castanheira","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026012903423513100_dlaf260-B3","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.cmi.2016.01.016","article-title":"Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"22","author":"Falcone","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2026012903423513100_dlaf260-B4","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/cid\/ciad100","article-title":"Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative bacilli: results from a nationwide study in Italy (ALARICO network)","volume":"76","author":"Falcone","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026012903423513100_dlaf260-B5","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing Enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026012903423513100_dlaf260-B6","doi-asserted-by":"publisher","first-page":"106611","DOI":"10.1016\/j.ijantimicag.2022.106611","article-title":"Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM)","volume":"60","author":"Tiseo","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2026012903423513100_dlaf260-B7","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026012903423513100_dlaf260-B8","doi-asserted-by":"publisher","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections","author":"Tamma","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026012903423513100_dlaf260-B9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2026012903423513100_dlaf260-B10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0140-6736(24)02081-6","article-title":"Multidrug-resistant Gram-negative bacterial infections","volume":"405","author":"Macesic","year":"2025","journal-title":"Lancet"},{"key":"2026012903423513100_dlaf260-B11","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1093\/jac\/dkaf206","article-title":"Characterization of carbapenemase-producing Enterobacterales isolated from patients returning from sub-Saharan Africa, France, 2015\u20132022","volume":"80","author":"Poignon","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026012903423513100_dlaf260-B12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jhin.2025.07.003","article-title":"Characterization of the environment of patients colonized with carbapenemase-producing organisms: role of air and surfaces in the dissemination of key resistance genes","volume":"164","author":"Richer-Fortin","year":"2025","journal-title":"J Hosp Infect"},{"key":"2026012903423513100_dlaf260-B13","doi-asserted-by":"publisher","first-page":"dlae141","DOI":"10.1093\/jacamr\/dlae141","article-title":"Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline","volume":"6","author":"Haidar","year":"2024","journal-title":"JAC Antimicrob Resist"},{"key":"2026012903423513100_dlaf260-B14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10096-022-04526-0","article-title":"Progressive in vivo development of resistance to cefiderocol in Pseudomonas aeruginosa","volume":"42","author":"Sadek","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026012903423513100_dlaf260-B15","doi-asserted-by":"publisher","first-page":"107630","DOI":"10.1016\/j.ijantimicag.2025.107630","article-title":"Epidemiology, treatment and outcomes of bloodstream infections due to MBL-producing Enterobacterales in France: a retrospective study","volume":"66","author":"Pilmis","year":"2025","journal-title":"Int J Antimicrob Agents"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlaf260\/66322228\/dlaf260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/8\/1\/dlaf260\/66322228\/dlaf260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:42:47Z","timestamp":1769676167000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf260\/8417993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf260","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,7]]},"article-number":"dlaf260"}}